|Bid||188.66 x 800|
|Ask||188.72 x 1100|
|Day's Range||188.47 - 190.28|
|52 Week Range||114.27 - 194.61|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 26, 2020 - Jan 30, 2020|
|Forward Dividend & Yield||2.96 (1.54%)|
|Ex-Dividend Date||Nov 10, 2019|
|1y Target Est||190.14|
Allergan plc (NYSE: AGN) announced today the launch of the SkinMedica® Instant Bright Eye Cream, a refreshing eye treatment that hydrates, brightens and helps visibly firm the appearance of the delicate skin around the eyes. The product is designed to immediately improve the appearance of the eyes and continues reducing the visible signs of aging and fatigue over time—including dark circles, fine lines and crepiness of upper eyelids. For its most comprehensive regimen, SkinMedica® is also introducing Instant Bright Eye Mask, a set of hydrogel eye patches that reduce the appearance of puffiness and provide a hydrating boost for under the eyes.
Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, announced today a partnership with Von Miller, Super Bowl MVP, Denver Broncos linebacker and advocate for healthy vision, to shine a light on the millions of people living with glaucoma. As an ambassador for the 'My Glaucoma' campaign, Miller will address the misunderstandings and impact of glaucoma and encourage those with the disease, and their caregivers, to take early action. This includes going regularly to the doctor and taking medications as prescribed. Additional information can be found at www.MyGlaucoma.com.
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of AbbVie Inc. New York, January 14, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of AbbVie Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.